March 2023, Vol 4, No 1

Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.

The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Results are presented from a retrospective analysis of molecular profiles in patients with biliary tract cancers to assess the efficacy of immune checkpoint inhibitors according to KRAS mutation.

Second-line treatment options for patients with advanced biliary tract cancer are limited. Results from a randomized phase 2 study aimed at evaluating nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in patients with metastatic disease are presented.

A recent epidemiological study showed that the incidence of cholangiocarcinoma has been increasing in the United States, and researchers sifted the data with an aim to help plan prevention and treatment strategies.

Researchers investigated risk factors for intrahepatic cholangiocarcinoma and the prognostic significance of tumor multiplicity identified by surgical resection.

A retrospective review was conducted using the hidden-genome classifier to quantify the genetic heterogeneity of intrahepatic cholangiocarcinoma with a view toward improved tumor classification.

The clinical benefit of durvalumab plus GemCis in patients with advanced cholangiocarcinoma has been proved, but affordability of the regimen remains a concern. A cost analysis of this treatment regimen considers issues related to outcomes versus the financial toxicity experienced by patients.